|Bid||0.00 x 1000|
|Ask||0.00 x 1100|
|Day's Range||9.81 - 10.42|
|52 Week Range||9.15 - 21.30|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.27|
DURHAM, N.C., November 09, 2021--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Benjamin McGraw, III, Pharm.D., Interim Executive Chairman, will participate in the following virtual investor conferences.
Thank you for standing by, and welcome to the Aerie Pharmaceuticals Third Quarter 2021 Earnings Conference Call. It is now my pleasure to turn the floor over to Aerie's General Counsel, John LaRocca. With us today are Ben McGraw, Aerie's Interim Executive Chairman; Tom Mitro, Aerie's President and Chief Operating Officer; David Hollander, Aerie's Chief Research and Development Officer; Casey Kopczynski, Aerie's Chief Scientific Officer; and Jeff Calabrese, Aerie's Vice President of Finance and Principal Accounting Officer.
Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.